Accessibility Menu
Medexus Pharmaceuticals logo

Medexus Pharmaceuticals

(TSX) MDP

Current PriceCA$4.20
Market CapCA$130.49M
Since IPO (2013)-44%
5 Year-42%
1 Year+33%
1 Month+8%

Medexus Pharmaceuticals Financials at a Glance

Market Cap

CA$130.49M

Revenue (TTM)

$99.33M

Net Income (TTM)

-$2.39M

EPS (TTM)

-CA$0.10

P/E Ratio

-244.85

Dividend

CA$0.00

Beta (Volatility)

0.93 (Low)

Price

CA$4.20

Volume

79,286

Open

CA$4.04

Previous Close

CA$4.20

Daily Range

CA$3.94 - CA$4.29

52-Week Range

CA$2.47 - CA$4.29

Estimated Earnings Date

Aug 18, 2026

MDP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medexus Pharmaceuticals

Industry

Pharmaceuticals

Employees

90

CEO

Kenneth d’Entremont

Headquarters

Toronto, ON M5C 1C3, CA

MDP Financials

Key Financial Metrics (TTM)

Gross Margin

54.78%

Operating Margin

5.18%

Net Income Margin

-2.41%

Return on Equity

-4.64%

Return on Capital

8.19%

Return on Assets

-1.63%

Earnings Yield

-0.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$130.49M

Shares Outstanding

32.30M

Volume

79.29K

Avg. Volume

47.75K

Financials (TTM)

Gross Profit

$54.41M

Operating Income

$5.14M

EBITDA

$12.59M

Operating Cash Flow

$18.87M

Capital Expenditure

-$15.15M

Free Cash Flow

$3.72M

Cash & ST Invst.

$6.52M

Total Debt

$22.26M

Medexus Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$24.65M

-0.4%

Gross Profit

$13.27M

+6.8%

Gross Margin

53.84%

N/A

Market Cap

CA$130.49M

N/A

Market Cap/Employee

CA$1.43M

N/A

Employees

91

N/A

Net Income

-$2.68M

-383.7%

EBITDA

$475.00K

-87.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$6.52M

-72.8%

Total Debt

$22.26M

-40.1%

Accounts Receivable

$14.86M

+11.7%

Inventory

$33.30M

-5.6%

Long Term Debt

$20.05M

+10026.8%

Short Term Debt

$2.21M

-94.0%

Return on Assets

-1.63%

N/A

Return on Invested Capital

5.49%

N/A

Free Cash Flow

-$11.22M

-604.5%

Operating Cash Flow

$3.79M

+66.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRDL.TOCardiol Therapeutics Inc.
CA$1.51+0.00%
DB.VDecibel Cannabis Company Inc.
CA$0.12+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$153.23+0.00%
KEELKeel Infrastructure
$6.03+0.03%
SOFISoFi Technologies
$17.88+0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.67+0.04%

Questions About MDP

What is the current price of Medexus Pharmaceuticals?

Medexus Pharmaceuticals is trading at CA$4.20 per share.

What is the 52-week range for Medexus Pharmaceuticals?

Over the past 52 weeks, Medexus Pharmaceuticals has traded between CA$2.47 and CA$4.29.

How much debt does Medexus Pharmaceuticals have?

As of the most recent reporting period, Medexus Pharmaceuticals reported total debt of $31.07M.

How much cash does Medexus Pharmaceuticals have on hand?

Medexus Pharmaceuticals reported $9.10M in cash and cash equivalents in its most recent financial results.

What is Medexus Pharmaceuticals’s dividend yield?

Medexus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.